NCAM1 and cancer: Among these, strategies of certain interest include the use of CIK cells (a heterogeneous population of effector CD3+CD56+ NK T cells) combined with the anti-PD-1 drug camrelizumab (NCT03987698) and the chance to combine polyethylene glycolylated IL-2 (NKTR-214) to VB10.NEO, an individualized DNA plasmid cancer vaccine [123].